Health Science Reports (Aug 2023)

Nanoplatforms: The future of oral cancer treatment

  • Kalpani Senevirathna,
  • Shalindu M. Jayawickrama,
  • Yovanthi A. Jayasinghe,
  • Karunakalage I. P. Prabani,
  • Kushani Akshala,
  • Ratupaskatiye G. G. R. Pradeep,
  • Hewaratne D. W. T. Damayanthi,
  • Kalani Hettiarachchi,
  • Thinley Dorji,
  • Don E. Lucero‐Prisno,
  • Rajapakse M. G. Rajapakse,
  • Kehinde K. Kanmodi,
  • Ruwan D. Jayasinghe

DOI
https://doi.org/10.1002/hsr2.1471
Journal volume & issue
Vol. 6, no. 8
pp. n/a – n/a

Abstract

Read online

Abstract Background and Aims Cytotoxicity is a key disadvantage of using chemotherapeutic drugs to treat cancer. This can be overcome by encapsulating chemotherapeutic drugs in suitable carriers for targeted delivery, allowing them to be released only at the cancerous sites. Herein, we aim to review the recent scientific developments in the utilization of nanotechnology‐based drug delivery systems for treating oral malignancies that can lead to further improvements in clinical practice. Methods A comprehensive literature search was conducted on PubMed, Google Scholar, ScienceDirect, and other notable databases to identify recent peer‐reviewed clinical trials, reviews, and research articles related to nanoplatforms and their applications in oral cancer treatment. Results Nanoplatforms offer a revolutionary strategy to overcome the challenges associated with conventional oral cancer treatments, such as poor drug solubility, non‐specific targeting, and systemic toxicity. These nanoscale drug delivery systems encompass various formulations, including liposomes, polymeric nanoparticles, dendrimers, and hydrogels, which facilitate controlled release and targeted delivery of therapeutic agents to oral cancer sites. By exploiting the enhanced permeability and retention effect, Nanoplatforms accumulate preferentially in the tumor microenvironment, increasing drug concentration and minimizing damage to healthy tissues. Additionally, nanoplatforms can be engineered to carry multiple drugs or a combination of drugs and diagnostic agents, enabling personalized and precise treatment approaches. Conclusion The utilization of nanoplatforms in oral cancer treatment holds significant promise in revolutionizing therapeutic strategies. Despite the promising results in preclinical studies, further research is required to evaluate the safety, efficacy, and long‐term effects of nanoformulations in clinical settings. If successfully translated into clinical practice, nanoplatform‐based therapies have the potential to improve patient outcomes, reduce side effects, and pave the way for more personalized and effective oral cancer treatments.

Keywords